OPSSF Archives - BioTuesdays

Developments

OpSens completes enrollment in SavvyWire study in Europe

OpSens (TSX:OPS; OTCQX:OPSSF) completed enrollment in the SAFE–TAVI clinical study, which is studying left ventricular rapid pacing using SavvyWire in transcatheter aortic valve implantation (TAVI or TAVR) procedures...

April 11, 2023

Executive Moves

OpSens names John Hannigan as CFO

OpSens (TSX:OPS; OTCQX:OPSSF) appointed John Hannigan as CFO, effective immediately. Mr. Hannigan is a highly experienced financial executive with more than 22 years of proven financial expertise with domestic and...

March 27, 2023

Developments

OpSens in specialty diagnostics pact with Premier for SavvyWire

OpSens (TSX:OPS; OTCQX:OPSSF) was awarded a national group purchasing agreement for interventional specialty diagnostics with Premier, a leading healthcare improvement company uniting an alliance with approximately...

March 14, 2023

Developments

OpSens starts SavvyWire study in Europe

OpSens (TSX:OPS; OTCQX:OPSSF) announced the successful completion of the first cases in a clinical study, named SAFE-TAVI, studying SavvyWire left ventricular rapid pacing in transcatheter aortic valve replacement...

October 26, 2022

Feature

OpSens SavvyWire tackling cardiology with advanced optical devices

With last month’s FDA clearance of the SavvyWire transcatheter aortic valve replacement (TAVR) guidewire, OpSens (TSX:OPS; OTCQX:OPSSF) is bringing a new concept to interventional cardiology and the delivery of new...

October 18, 2022

Developments

OpSens SavvyWire in first U.S. procedure

Dr. Philippe Genereux, director of the Structural Heart Program at Morristown Medical Center in New Jersey, and his team, performed the first use of OpSens’ (TSX:OPS; OTCQX:OPSSF) SavvyWire in a transcatheter aortic...

September 23, 2022

Developments

FDA clears OpSens SavvyWire for transcatheter aortic valve replacement

OpSens (TSX:OPS; OTCQX:OPSSF) received 510(k) regulatory clearance from the FDA for SavvyWire, its new guidewire for transcatheter aortic valve replacement procedures, or TAVR. In a statement, Louis Laflamme, president...

September 15, 2022

Developments

OpSens files 510(k) submission for new guidewire for TAVR procedure

OpSens (TSX:OPS; OTCQX:OPSSF) filed a 510(k) submission with the FDA for regulatory clearance of its new SavvyWire guidewire for transcatheter aortic valve replacement, or TAVR procedures. OpSens previously filed for...

December 13, 2021

Developments

Health Canada clears first-in-man study of OpSens guidewire

OpSens (TSX:OPS; OTCQX:OPSSF) received Health Canada’s approval to begin a first in-man study with its SavvyWire, a guidewire developed specifically for transcatheter aortic valve replacement (TAVR). ...

September 20, 2021

Developments

Opsens in first clinical use of OptoWire III after Health Canada approval

Opsens (TSX:OPS; OTCQX:OPSSF) announced the world’s first clinical use of its OptoWire III at the Quebec Heart and Lung Institute, following Health Canada’s recent approval of the device. OptoWire III is a...

November 7, 2019

Tag - OPSSF

OpSens completes enrollment in SavvyWire study in Europe

OpSens names John Hannigan as CFO

OpSens in specialty diagnostics pact with Premier for SavvyWire

OpSens starts SavvyWire study in Europe

OpSens SavvyWire tackling cardiology with advanced optical devices

OpSens SavvyWire in first U.S. procedure

FDA clears OpSens SavvyWire for transcatheter aortic valve replacement

OpSens files 510(k) submission for new guidewire for TAVR procedure

Health Canada clears first-in-man study of OpSens guidewire

Opsens in first clinical use of OptoWire III after Health Canada approval

General

More